**Evaluation of three STA-1474 dosing regimens in Dogs with Mast Cell Tumors**

This study evaluates the effects of a new heat shock protein 90 (HSP90) inhibitor, STA-1474, to decrease Kit protein levels in mast cell tumors (MCTs) and thereby cause them to regress.

**Eligibility:**
- Must have a cytologic or histologic diagnosis of MCT
- Must have adequate organ function
- Has an expected life expectancy of at least 8 weeks
- Prior radiation therapy or chemotherapy must have been completed at least 3 weeks prior to study entry.

**Client compensation:**
- The study will cover all fees associated with the study
- Client will receive a $1000 credit at the Veterinary Medical Center upon completion of study

Contact: Dr. Cheryl London

**Study of the Effects of Pimobendan on Hypertrophic Cardiomyopathy**

The purpose of this study is to determine if Pimobendan, an inodilator drug, will improve morbidity and mortality in cats with hypertrophic cardiomyopathy (HCM) and congestive heart failure (CHF). This is a prospective, double-blind, placebo-controlled, multi-center study.

**Eligibility:**
- Cats with HCM and CHF

**Client compensation:**
- The study sponsor will cover all costs related to the study up to $7,500

Contact: Dr. Karsten Schober
Upcoming Studies-Continued

Evaluation of Pimobendan in Dogs with Cardiomegaly Caused by Preclinical Mitral Valve Disease - EPIC

This is a placebo controlled double blind study evaluating if treatment with pimobendan will significantly delay the onset of CHF in dogs with advanced mitral disease and significant cardiac remodeling as evidenced by clinical signs and thoracic radiography.

Eligibility:

- Echocardiographic evidence of myxomatous mitral valve disease
- Radiographic evidence of cardiomegaly
- Animals must be at least six years of age
- Animals must have a body weight of ≥ 4.1 and ≤ 15 kg

Client compensation:

- The sponsor will cover all costs associated to the study.

Contact: Dr. John Bonagura

Clinical Trial Patient Highlight

Cancer, a time to celebrate? We all know that the decision to treat cancer is never easy, but for Forest and her owner the decision to treat gave them a reason to celebrate! Meet Forest, she is a 9 year old mixed breed dog that was diagnosed with osteosarcoma. Her owner opted to amputate the affected leg and follow up with chemotherapy. At that time, the CTO was enrolling dogs in a clinical evaluating the combination of carboplatin and gemcitabine in dogs with osteosarcoma. Forest’s owner decided to enroll her in the trial and she received 4 doses of carboplatin and gemcitabine in combination.

Unfortunately 8 months after the amputation, there was evidence of lung metastasis on thoracic radiographs. Her owner was given different treatment options and decided to go with another trial that combined Palladia (toceranib phosphate) and cyclophosphamide. Although this combination had not officially been evaluated in veterinary medicine, there was anecdotal evidence that it might be active in dogs with various types of tumors.

This month, Forest and her owner celebrated the 2 year anniversary of her OSA diagnosis. At her last recheck appointment thoracic radiographs showed stable disease. Forest continues with her mischievous ways, recently escaping to roam the streets of Cleveland before returning home.
Dr. Cheryl London, a board certified oncologist, and Dr. Roberta Portela, oncology clinical trial intern, are looking for dogs diagnosed with MCT to determine if canine mast cell tumors with kit mutation respond better to Palladia and whether screening for Kit mutations play a role in treatment decision-making.

Eligibility:
- Confirmed measurable MCT
- Life expectancy of at least 12 weeks

Client compensation:
- Study covers initial biopsy and the majority of each visit
- Patients on the Palladia arm will receive drug free of cost indefinitely

Client Cost
- Owner is responsible for initial office visit and screening tests including bloodwork and abdominal ultrasound (approx. $850)
- Each visit the owner is responsible for $25; dogs receiving Vinblastine will be responsible for additional $20 at each treatment.

Dr. Sandra Barnard, a board-certified oncologist, and Dr. Dennis Chew, a board-certified internist, are studying transitional cell carcinoma of the urinary bladder, which is a frustrating disease to treat. Current therapies have very low response rates, and assessing tumor response via ultrasound is inaccurate and misleading. This study aims to assess the treatment response of a combination of vinblastine and Palladia while using both CT and ultrasound to evaluate how to accurately measure these tumors.

Eligibility Criteria
- Confirmed diagnosis of TCC
- No prior treatment with chemotherapy. Previous treatment with NSAID’s and surgery are accepted

Client compensation:
- The study will apply approx. $4500 towards chemotherapy, CT scan, and cystoscopy
- Palladia will be provided free of charge for 6 months after the study is completed

Client Cost
- Owner is responsible for the initial office visit (approx. $450)
- For each treatment visit the owners are responsible for $57
New Recruiting Clinical Trials

Phase I Evaluation of Gold Nanorods in Dogs with Solid Tumors

Gold nanorods will be used to help kill tumor cells following laser treatment.

Eligibility:
- Diagnosed with an external solid tumor
- Expected life expectancy of at least 6 weeks
- Has not received chemotherapy or radiation within 3 weeks
- Tumor must be amenable to repeat biopsy
- No evidence of underlying cardiac disease

Client compensation:
- The study will cover all fees associated with the study
- Client is responsible for the initial office visit

Dr. Cheryl London and Dr. Roberta Portela are conducting a project that will be the first of its kind using a novel form of therapy to treat solid tumors.

College News

Annual Open House

Every year The Ohio State University College of Veterinary Medicine opens its doors to the public. This Annual Open House allows pet owners, farmers, and all animal lovers the opportunity to learn more about animal care and health.

- Saturday, May 21, 2011
- 9 a.m. – 4 p.m. (rain or shine)
- Admission is FREE!
- http://vet.osu.edu/AnnualOpenHouse

OSU CVM Ranked 5th

The Ohio State University College of Veterinary Medicine continues a trend of excellence by maintaining its fifth-place ranking among the 28 veterinary colleges in North America.

"Ohio State is the only veterinary school in the country on a campus with a comprehensive medical center offering seven health sciences colleges," said Lonnie J. King, dean and Ruth Stanton Chair in Veterinary Medicine. "We are proud to be recognized among the top in the nation, and plan to continue to provide leadership in the field as we strive to ensure a healthier world."
Hospital Updates

*Renovations Facilitate Leading-Edge Patient Care*

The Ohio State University Veterinary Medical Center continually strives to be the best, and it now has newly renovated leading-edge facilities to excel in that quest. Approximately nine months of facility renovations has led to completion this month of over 4,600 square feet of state-of-the-art space in our patient care and client service areas. The space includes:

- A Small Animal Internal Medicine Suite, complete with exam and treatment spaces, and a single work environment for all member of the team, said Dr. Sue Johnson, head of the service. And on the education front, a student learning center within the area provide future veterinarians with the tools they need to further their knowledge.

- Four new small animal exam rooms which will enhance our ability to see more patients, reduce wait time for clients, and improve teaching.

- An Oncology Suite that now allows patients to be treated in a dedicated and private chemotherapy room, with expanded facilities for exams, treatment, and teaching. The VMC’s Oncology and Hematology Service has a very large caseload and the practice continues to grow annually. The renovations will only enhance that expansion, explained Dr. Couto. “Our motto for patients who need cancer care is, ‘Come on down,’” said Dr. Couto, who is in his 29th year at the VMC.

- A Blood Bank collection, testing and processing area for blood and blood products. “When we started, we were in a space the size of a closet, and then three years ago we moved to an area the size of a walk-in closet,” said Dr. Couto.

- A Dentistry and Minor Procedures Suite equipped with new digital radiograph viewers on every table that enable students to see all procedures, improving their education and future technique. “We can accommodate a lot more with more space.” said veterinary technician Dawn Eblin. It should reduce the wait time dramatically for our clients.

- An Interventional Medicine/Radiology Suite where surgeries are performed without cutting that offers “open-heart” results with “closed-chest” procedures. The state-of-the-art imaging equipment has now revolutionized already state-of-the-art treatments, allowing for imaging-guided procedures and the use of fluoroscopy unit to provide real-time x-rays.

“Our newly renovated and expanded clinical spaces will enable us to provide the most advanced treatment options available for our companion animal patients,” said Dr. Rustin Moore, Associate Dean of Clinical and Outreach Programs.
Cardiology

- Acute Effect of Ivabradin, a Novel If Current Inhibitor, on Dynamic Obstruction of the Left Ventricular Outflow Track in Cats with Preclinical Hypertrophic Cardiomyopathy
  - Cats with asymptomatic, stable HCM that are currently not on any treatment
  - **Client receives $220 toward study costs**

- The Acute Effects of Pimbendam on the Left Atrial and Auricular Function: An Echocardiographic Study in Cats with Cardiomyopathy and Stable Congestive Heart Failure
  - Diagnosed congestive heart failure that has been well controlled for at least 7 days
  - **Study covers all visits associated with the study; clients are responsible for initial work-up**

Equine

- Cell-Mediated Bone Morphogenetic Protein Gene Therapy for Bone Healing in Horses
  - Confirmed diagnosis of a fracture or subchondral cone cysts
  - **The study covers biopsy and therapy application**

Internal Medicine

- Pilot Test of a Method to Relax the Ureter of Animals to Facilitate Passage of Ureteral Stone
  - Female dog with confirmed ureteral stones
  - **The study will pay $750 of the costs and any Adverse Events up to $2000**

Neurology

- Kinetic and Kinematic Gait Analysis of Doberman Pinchers With or Without Clinical Signs of Cervical Spondylomyelopathy
  - Any Doberman Pincher diagnosed with cervical spondylomyelopathy
  - Any clinically normal Doberman Pincher
  - **Study covers all visits associated with the study; clients are responsible for initial work-up**

Oncology

- Maintenance Therapy with Toceranib (Palladia) Following Doxorubicin-Based Chemotherapy for Canine Splenic Hemangiosarcoma
  - Histologically confirmed splenic hemangiosarcoma
  - Must receive 5 doses of doxorubicin (30 mg/m2) every 2 wks post surgery
  - **Study covers restaging prior to starting Palladia, free Palladia, and all follow-up blood work**

- Analysis of Palladia Pharmacokinetics and Pharmacodynamics at Non-Labeling Dosing
  - Dogs with a sarcoma, carcinoma, melanoma or other solid tumor
  - **Palladia will be provided at no cost during and 6 months after completion of the study**

- Impact of Palladia/Piroxicam/Cyclophosphamide Maintenance Therapy on the Survival Time of Dogs with Appendicular Osteosarcoma Following Amputation and Carboplatin Chemotherapy
  - Histologically confirmed diagnosis of OSA
  - **The study covers the cost of Carboplatin and Palladia, as well as providing a total of approximately $650 towards recheck visits.**
Ongoing Clinical Trials

- A Multi-Center Study Examining the Efficacy of Palladia as a Primary and/or Adjuvant in the Treatment of Feline Oral Squamous Cell Carcinoma
  - Confirmed diagnosis of feline oral SCC
  - **Palladia will be provided at no cost for the duration of the study**

- Examining the Efficacy of Palladia as a Primary and/or Adjuvant in the Treatment of Canine Nasal Carcinoma: A Multicenter Study
  - Histologically confirmed nasal carcinoma
  - **The study will cover most recheck visits and tests (bloodwork, CT scans) performed after the Palladia therapy is initiated representing a savings of approximately $3100**

**Ophthalmology**

- Clinical Assessment of the Use of SentrX KCS Treatment Gel in Reducing Clinical Symptoms Associated with Keratoconjunctivitis Sicca (KCS) in Dogs
  - Confirmed diagnosis of Canine KCS
  - **All study medication and examinations will be covered by the study**

- Treatment of Canine Keratoconjunctivitis Sicca with an Aqueous Formulation of Cyclosporine
  - Confirmed diagnosis of Canine KCS
  - **All study medication and follow-up examinations will be covered by the study**

- The Histological Effect of Semi-Conductor Diode Laser Trans-Scleral Cyclophotocoagulation on Buphthalmic Equine Globes
  - Horses with a blind glaucomatous eye that are already undergoing general anesthesia to have the eye removed
  - **Study covers histologic processing of the globe and will deduct $100 from the client bill**

**Orthopedics**

- Pilot Clinical Trial on the Use of Intra-articular Platelet Concentrate to Improve Lameness in Dogs with Osteoarthritis
  - Have stifle or elbow osteoarthritis on radiographic imaging
  - **Kinetic analysis, sample collection, and treatment are covered by the study; and all fees related to recheck visits pertaining to the study such as physical exam, x-rays, and kinetic analysis are covered by the study**

---

What’s New in the CTO

Start following us on Facebook and Twitter to receive the most current information about our clinical trials.
Do you see patients with Wobbler Syndrome?

Looking for dogs to participate in a Kinetic and Kinematic Gait Analysis of Doberman Pinchers With Clinical Signs of Cervical Spondylomyelopathy Clinical Trial.

**Purpose of Study**

The purpose of this study is to establish a reference ranges for normal gait in Doberman Pinchers and using this data, be able to precisely compare and identify the superiority of treatment methods for cervical spondylomyelopathy (CSM).

Wobbler syndrome, known as cervical spondylomyelopathy (CSM), is a common spinal disease of large breed dogs, with the Doberman being the most affected. This disease is diagnosed using computed tomography (CT), magnetic resonance imaging (MRI), or myelography. Currently, there is no specific treatment method proven to be the most effective. The main reason for this is a lack of an appropriate way to assess the dogs’ response to treatment. Most patients’ responses are based on gait exam and the owner’s assessment. As such, mild changes can go unnoticed.

This study involves using two computerized systems to evaluate the gait of normal Doberman Pinscher and Dobermans affected with Wobblers syndrome. The first part the study involves obtaining data on the gait of clinically normal Doberman Pinchers as a means of establishing normal parameters in order to compare that to Doberman Pinchers affected with Wobblers syndrome. We will then compare the results of the computerized assessment with the gait exam and the owner’s perception of improvement, thus demonstrating that the computerized gait analysis provides a more accurate reflection of the dog’s response to treatment.

**Inclusion criteria**

- Any Doberman Pincher diagnosed with cervical spondylomyelopathy

_Susana del Rio Kuroiwa, Ronaldo da Costa and Jenny Novelli work with Novelli’s Doberman as Kari Foss, counts the number of reflective markers on Slick’s bodysuit._

**Clinical Trial Updates**
Study Design

CSM Dobermans will have an initial visit consisting of a physical exam, blood draw, and a complete neurologic exam then MRI will be scheduled at the owner’s nearest convenience. Once a MRI is performed, the next visit will involve obtaining the kinetic and kinematic data. Following the collection of the initial kinetic and kinematic data, treatment can be initiated. CSM treatment can be either medical or surgical, and will be decided on a per patient basis. Dogs will need to come in for a recheck neurologic exam at 4 and 8 weeks after treatment initiation. The 8 week visit will also include a repeat of kinetic and kinematic analysis.

Client Compensation

- The study covers the 2 recheck visits (weeks 4 and 80, MRI, and kinetic and kinematic gait analysis for CSM Dobermans

Client Cost

- The owner is responsible for the cost of initial screening along with any diagnostics that need to be performed

- Owners are also responsible for the costs related to the standard of care treatment for cervical spondylomyelopathy whether it be surgical or medical

Contact Information

Dr. Ronaldo da Costa
Email: dacosta.6@osu.edu